5807-02-3

Basic information

• Product Name: MORPHOLINOACETONITRILE
• Synonyms: N-ACETONITRILE MORPHOLINE;MORPHOLINOACETONITRILE;N-CYANOMETHYLMORPHOLINE;4-morpholineacetonitrile;morpholino-acetonitril;4-morpholinoacetonitrile;2-(Morpholin-4-yl)acetonitrile
• CAS NO: 5807-02-3
• Molecular Formula: C₆H₁₀N₂O
• Molecular Weight: 126.16
• EINECS: 227-366-6
• Mol File: 5807-02-3.mol
• Article Data: 12

Chemical Properties

• Melting Point: 62°C
• Boiling Point: 124 °C / 23mmHg
• Flash Point: 87 °C
• Appearance: /
• Density: 1.055 g/cm³
• Vapor Pressure: 0.114mmHg at 25°C
• Refractive Index: 1.462
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 2.79±0.10(Predicted)
• CAS DataBase Reference: MORPHOLINOACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: MORPHOLINOACETONITRILE(5807-02-3)
• EPA Substance Registry System: MORPHOLINOACETONITRILE(5807-02-3)

Safety Data

• Statements: 23/24/25-36/37/38
• Safety Statements: 36/37/39
• RIDADR: 2811
• RTECS: QD6650000
• HazardClass: IRRITANT
• PackingGroup: II
• Hazardous Substances Data: 5807-02-3(Hazardous Substances Data)

Usage

General Description

Morpholinoacetonitrile is a chemical compound with the molecular formula C5H9NO. It is a colorless liquid with a pungent odor, and it is commonly used as a reagent in organic synthesis. Morpholinoacetonitrile is a versatile intermediate in the production of pharmaceuticals, agrochemicals, and other fine chemicals. It is often used as a building block in the synthesis of complex molecules due to its ability to undergo various chemical reactions, such as nucleophilic addition and substitution. MORPHOLINOACETONITRILE is also known for its use as a stabilizer in electroplating processes and as a solvent in the manufacturing of specialty chemicals. However, it is important to handle morpholinoacetonitrile with care, as it is toxic and can cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C6H10N2O/c7-1-2-8-3-5-9-6-4-8/h2-6H2

Upstream product

• 110-91-8 morpholine 
• 50-00-0 formaldehyd 
• 74-90-8 hydrogen cyanide 
• 151-50-8 potassium cyanide 
• 77-78-1 dimethyl sulfate 
• 107-14-2 chloroacetonitrile 
• 590-17-0 cyanomethyl bromide 
• 107-16-4 glycolonitrile 

Downstream Products

• 849682-30-0 4-(2-morpholin-4-ylmethylthiazol-4-yl)benzoic acid 
• 112081-99-9 (E)-2-Morpholin-4-yl-4-nitro-3-phenyl-but-2-enenitrile 
• 100-47-0 benzonitrile 
• 104-85-8 para-methylbenzonitrile 
• 874-90-8 4-methoxybenzonitrile 
• 1194-02-1 4-fluorobenzonitrile 
• 623-03-0 4-Cyanochlorobenzene 
• 619-72-7 4-nitrobenzonitrile 
• 623-26-7 terephthalonitrile 
• 1443-80-7 4-cyanophenyl methyl ketone 
• 105-07-7 4-cyanobenzaldehyde 
• 21382-98-9 p-cyanophenyl methyl sulfide 
• 620-22-4 3-Methylbenzonitrile 
• 6609-56-9 2-methoxy-benzonitrile 

Relevant articles and documents

Towards the total synthesis of colletofragarones: constructing the macrocyclic lactone by high pressure-mediated intramolecular Diels-Alder reaction

We report herein an intramolecular Diels-Alder approach towards the construction of the macrocyclic lactone ring and the perhydrobenzofuran system of the colletofragarones, novel metabolites produced by fungi of the genus Colletotrichum that are responsib

Bicyclic alkaloid compound, preparation method and applications thereof

The present invention relates to a bicyclic alkaloid compound, or a tautomer, a stereoisomer, a racemate, the non-equal mixture of enantiomers, a geometric isomer, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceutical composition containing the compound. The invention further discloses uses of the compounds and the pharmaceutical composition thereof as drugs, especially as anti-inflammatory drugs and anti-fibrotic drugs.

Nitrogenous Heterocyclic Derivatives And Their Application In Drugs

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.